SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

@article{Byfield2004SB505124IA,
  title={SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.},
  author={Stacey DaCosta Byfield and Christopher Major and Nicholas J Laping and Anita B. Roberts},
  journal={Molecular pharmacology},
  year={2004},
  volume={65 3},
  pages={744-52}
}
  • Stacey DaCosta Byfield, Christopher Major, +1 author Anita B. Roberts
  • Published 2004 in Molecular pharmacology
Clinically, there is a great need for small molecule inhibitors that could control pathogenic effects of transforming growth factor (TGF-beta) and/or modulate effects of TGF-beta in normal responses. Inhibition of TGF-beta signaling would be predicted to enhance re-epithelialization of cutaneous wounds and reduce scarring fibrosis. Selective small molecule inhibitors of the TGF-beta signaling pathway developed for therapeutics will also be powerful tools in experimentally dissecting this… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS